4/25
07:12 am
ions
Ionis Publishes 2023 Corporate Responsibility Report [Yahoo! Finance]
Low
Report
Ionis Publishes 2023 Corporate Responsibility Report [Yahoo! Finance]
4/25
07:00 am
ions
Ionis Publishes 2023 Corporate Responsibility Report
Low
Report
Ionis Publishes 2023 Corporate Responsibility Report
4/24
09:12 am
ions
n-Lorem Foundation Partners with Hongene Biotech Corporation to Support the Discovery of Personalized ASO Medicines for Nano-rare Patients [Yahoo! Finance]
Low
Report
n-Lorem Foundation Partners with Hongene Biotech Corporation to Support the Discovery of Personalized ASO Medicines for Nano-rare Patients [Yahoo! Finance]
4/23
07:05 am
ions
Ionis to hold first quarter 2024 financial results webcast
Low
Report
Ionis to hold first quarter 2024 financial results webcast
4/18
09:28 am
ions
Bepirovirsen for Chronic Hepatitis B Drug Pipeline Report 2024: 7MM Market Size, Forecast, and Emerging Insights 2019-2032 [Yahoo! Finance]
Low
Report
Bepirovirsen for Chronic Hepatitis B Drug Pipeline Report 2024: 7MM Market Size, Forecast, and Emerging Insights 2019-2032 [Yahoo! Finance]
4/16
09:11 am
ions
n-Lorem Foundation Collaborates with Across Healthcare to Develop a Custom Submission Platform for Physicians of Nano-rare Patients [Yahoo! Finance]
Low
Report
n-Lorem Foundation Collaborates with Across Healthcare to Develop a Custom Submission Platform for Physicians of Nano-rare Patients [Yahoo! Finance]
4/10
09:15 am
ions
n-Lorem Foundation Announces the Second Annual Nano-rare Patient Colloquium Will be Held on Oct. 30 & 31, 2024 [Yahoo! Finance]
Low
Report
n-Lorem Foundation Announces the Second Annual Nano-rare Patient Colloquium Will be Held on Oct. 30 & 31, 2024 [Yahoo! Finance]
4/10
08:06 am
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating.
Low
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating.
4/9
11:17 am
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "outperform" rating re-affirmed by analysts at William Blair.
4/9
08:44 am
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $72.00 to $75.00. They now have an "outperform" rating on the stock.
Low
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $72.00 to $75.00. They now have an "outperform" rating on the stock.
4/9
08:09 am
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Low
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
4/7
09:48 am
ions
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Low
Report
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
4/4
07:07 am
ions
Flamingo Therapeutics Announces Participation in Upcoming Investor and Industry Conferences [Yahoo! Finance]
Low
Report
Flamingo Therapeutics Announces Participation in Upcoming Investor and Industry Conferences [Yahoo! Finance]
4/1
07:05 am
ions
Ionis to present at upcoming investor conferences
Low
Report
Ionis to present at upcoming investor conferences
3/28
07:21 am
ions
Ionis to hold olezarsen Phase 3 data webcast [Yahoo! Finance]
Low
Report
Ionis to hold olezarsen Phase 3 data webcast [Yahoo! Finance]
3/28
07:05 am
ions
Ionis to hold olezarsen Phase 3 data webcast
Low
Report
Ionis to hold olezarsen Phase 3 data webcast
3/25
08:44 am
ions
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting [Yahoo! Finance]
Low
Report
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting [Yahoo! Finance]
3/25
08:18 am
ions
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
Low
Report
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
3/22
12:58 pm
ions
Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
Low
Report
Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]
3/21
07:06 am
ions
Flamingo Therapeutics Appoints Leading Medical Oncologist Ezra Cohen, MD to its Board of Directors [Yahoo! Finance]
Low
Report
Flamingo Therapeutics Appoints Leading Medical Oncologist Ezra Cohen, MD to its Board of Directors [Yahoo! Finance]
3/19
07:06 am
ions
Health Canada Accepts for Review New Drug Submission for Tofersen for Treatment of Rare, Genetic Form of ALS [Yahoo! Finance]
Low
Report
Health Canada Accepts for Review New Drug Submission for Tofersen for Treatment of Rare, Genetic Form of ALS [Yahoo! Finance]
3/13
08:06 am
ions
Ionis stock jumps as MASH drug succeeds in mid-stage trial [Seeking Alpha]
Medium
Report
Ionis stock jumps as MASH drug succeeds in mid-stage trial [Seeking Alpha]
3/13
07:00 am
ions
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Low
Report
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
3/6
09:37 am
ions
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $65.00 to $72.00. They now have an "outperform" rating on the stock.
Low
Report
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $65.00 to $72.00. They now have an "outperform" rating on the stock.
2/29
09:19 am
ions
Ionis announces new chief global product strategy officer to lead next phase of commercial growth [Yahoo! Finance]
Low
Report
Ionis announces new chief global product strategy officer to lead next phase of commercial growth [Yahoo! Finance]